LV ejection fraction, which in itself may be related to reduced activity levels. Further, our data account for activity levels well outside the periimplantation window, which mitigates the impact of periprocedural complications on the relationship between activity time and mortality.
Severity of Metabolic Syndrome as a Predictor of Cardiovascular Disease Between Childhood and Adulthood The Princeton Lipid Research Cohort Study
The long-term ability of the metabolic syndrome (MetS) to predict cardiovascular disease (CVD) has been limited by the binary nature of traditional
MetS criteria and by discrepancies among African
Americans, who have low rates of MetS classification despite higher rates of death from CVD (1) . We previously used confirmatory factor analysis to formulate MetS severity z-scores for adolescents (2) and adults (3) that place differential weights on the individual MetS components to account for variation in how MetS is manifest by sex and racial/ethnic group.
Our goal was to assess the ability of these scores to Please note: This work was supported by National Institutes of Health grants 5K08HD060739 to Dr. DeBoer, U54GM104942 to Dr. Gurka, 1R21DK085363 to Drs. DeBoer and Gurka, 1R01HL120960 to Drs. DeBoer and Gurka, and National Heart, Lung, and Blood Institute N01HV22914; a University of Virginia Children's Hospital Grant-in-Aid (Charlottesville, Virginia) to Dr. DeBoer; a Cincinnati Children's Hospital Medical Center Heart Institute Research Core grant (Cincinnati, Ohio); a Schmidlapp Women's Scholar's Award (Cincinnati, Ohio) to Dr. Woo; and American Heart Association grant 9750129 (Chicago, Illinois) to Dr. Morrison. All authors were independent of these funding agencies. Drs. DeBoer and Gurka contributed equally to this work. Similarly, studies of anatomic plaque burden have typically not adjusted for high-risk plaque features.
R E F E R E N C E S
Given this, and that most imaging studies account for similar CV and demographic risk factors, it is instructive to compare the predictive value of selected studies comparing anatomic burden to vulnerable plaque (Table 1) . Notably, the adjusted risk estimates for death and/or major adverse cardiac events (MACE) are generally comparable for both plaque burden and plaque vulnerability char- 
